|
Laboratory data
|
Age (years)
|
AST (U/L)
|
ALT (U/L)
|
ALP (U/L)
|
Total bilirubin (mg/dL)
|
|---|
|
All cases (n = 796)
|
49 (0.03–94)
|
204 (10–7778)
|
217 (6–7000)
|
163 (32–3346)
|
2.9 (0.2–56.7)
|
|
Group I
|
48 (0.08–94)
|
195 (10–7778)
|
236 (7–6247)
|
163 (32–3346)
|
2.4 (0.2–49.4)
|
|
HEV IgG− HEV IgM− (n = 456)
|
|
Group II
|
50 (0.08–93)
|
185 (14–7000)
|
167 (6–7000)
|
170 (41–1422)
|
4.3 (0.2–56.7)
|
|
HEV IgG+ HEV IgM− (n = 233)
|
|
Group III
|
48.5 (4–59)
|
135.5 (30–915)
|
330 (19–1974)
|
212.5 (173–348)
|
1.6 (0.2–9.9)
|
|
HEV IgG− HEV IgM+ (n = 6)
|
|
Group IV
|
50 (0.03–91)
|
262 (16–3408)
|
343 (7–3383)
|
163 (51–1348)
|
3.9 (0.3–36.7)
|
|
HEV IgG+ HEV IgM+ (n = 101)
|
|
P-value
|
0.125
|
0.224
|
0.039*
|
0.573
|
0.017*
|
- A total number of 796 serum samples, which were sent for detection of both anti-HEV IgG and IgM antibodies, were analyzed according to the HEV serological status. General patient information and laboratory data, including age, AST, ALT, ALP, and total bilirubin, were demonstrated in median and range. Distributions across four HEV serological statuses (Group I: HEV IgG−/IgM−, Group II: HEV IgG+/IgM−, Group III: HEV IgG−/IgM+, and Group IV: HEV IgG+/IgM+) were compared using the Kruskal–Wallis test. A P-value less than 0.05 is considered statistical significance
